Peripheral blood-based cell signature indicates response to interstitial brachytherapy in primary liver cancer.

Sophia KästleMatthias R StecheleLisa RichterRegina SchinnerElif ÖcalMarianna Alunni-FabbroniEnrico De ToniStefanie CorradiniMax SeidenstickerS Nahum GoldbergJens RickeMoritz WildgruberMelanie A Kimm

Published in: Journal of cancer research and clinical oncology (2023)

Baseline blood-based cell signature may function as a biomarker to predict response following brachytherapy in primary liver cancer.

Keyphrases

peripheral blood
high dose
single cell
radiation therapy
stem cells
low dose
bone marrow